CPT® Code 80181

The CPT® Code 80181 refers to a laboratory test specifically designed to monitor therapeutic levels of flecainide, which is classified as an antiarrhythmic medication. Flecainide is primarily utilized in the management of various cardiac conditions, including paroxysmal supraventricular tachycardia, atrial fibrillation, atrial flutter, and life-threatening ventricular arrhythmias. The purpose of therapeutic drug monitoring is to ensure that the dosage of flecainide is optimized for each patient, thereby minimizing the risk of toxicity and ensuring adherence to the prescribed treatment regimen. Flecainide is administered orally and is known for its rapid absorption, achieving peak plasma levels approximately three hours post-administration. Steady-state concentrations are typically reached within three to five days of consistent dosing. The elimination of flecainide from the body occurs primarily through liver metabolism and renal excretion, with an average half-life of about 20 hours; however, this can vary significantly, ranging from 12 to 27 hours in adults, and approximately 8 hours in children. It is important to note that any impairment in liver or kidney function can significantly affect the elimination process of the drug. Patients may experience various adverse effects, including dizziness, visual disturbances, palpitations, nausea, fatigue, headaches, and shortness of breath. Therapeutic trough levels for flecainide are established between 0.2 to 1.0 mcg/mL, which are considered effective for suppressing premature ventricular contractions. Levels exceeding 1.0 mcg/mL indicate potential toxicity, which can manifest through severe symptoms such as hallucinations, joint pain, adverse cardiac events (including bradycardia, conduction defects, or asystole), respiratory failure, hypotension, and in extreme cases, death. To accurately assess the drug concentration, a blood sample is collected immediately before the next scheduled dose, processed by centrifugation to separate serum or plasma from blood cells, and analyzed using quantitative liquid chromatography-tandem mass spectrometry.